REGULATORY

• Trodelvy Up for Japan Panel Review on Sept. 12, Meiji COVID Jab on Agenda Too
  September 6, 2024

• Japan to Prepare Fact Sheets on RSV Vaccine, Antibody
  September 5, 2024

• Japan Poised to Launch FIH Trial System in FY2029 to Attract Global Seeds
  September 5, 2024

• Japan Healthcare Spend Hit Record High of 47 Trillion Yen in FY2023
  September 4, 2024

• Japan’s HIV and AIDS Cases Up for First Time in 7 Years
  September 4, 2024

• Don’t Stop Taking Atomoxetine at Own Discretion: MHLW to Patients
  September 4, 2024

• Japan Expects COVID Vaccine Supply of 32 Million Doses from 5 Makers in 2024-25
  September 3, 2024

• Takeda to Discontinue Kenketu Albuminate amid Falling Demand
  September 3, 2024

• METI Seeks 5.8 Billion Yen to Fund Biologic Manufacturing Technologies in FY2025
  September 2, 2024

• MHLW to Set AI Limit for Atomoxetine’s Nitrosamine Impurities at 100 ng/Day
  September 2, 2024

• Japan Panel OKs BMS ROS1 Inhibitor, Janssen Bispecific, JN.1-Targeted Nuvaxovid
  September 2, 2024

• LDP Study Group Mulls Seeking More Budget for Immunoglobulins in FY2025
  August 30, 2024

• FY2025 Budget Request Earmarks Funding to Systematize Collection of Drug Supply Info
  August 30, 2024

• MHLW Seeks 19.8 Billion Yen for Launch of Pandemic Agency JIHS in April
  August 30, 2024

• MHLW Requests Funds for Adding PMDA Reviewers, Subsidizing Advisory Fees in FY2025
  August 29, 2024

• MHLW to Seek Nearly 800 Million Yen to Boost New Modalities: FY2025 Budget Request
  August 29, 2024

• MHLW’s Tax Reform Request Not Yet Clear, HSC Debate Might Be a Cue
  August 29, 2024

• LDP Health Division OKs MHLW’s FY2025 Budget Request
  August 29, 2024

• NCGM President to Take Helm of Japan CDC after April Merger
  August 29, 2024

• Trintellix, Vtama Get 2-Year Extension of Re-Examination Period
  August 29, 2024

ページ

• « 先頭
• ‹ Prev
• …
• 40
• 41
• 42
• 43
• 44
• 45
• 46
• 47
• 48
• …
• Next ›
• 最終 »